Thursday, February 05, 2015 10:11:23 PM
Join our research scientists as they present two webinars to help you optimize the Iso-Seq™ method to meet your research goals. Each webinar will be presented twice (8 AM PST/5 PM PST) for live viewing and will also be recorded.
•Wednesday Feb 11: Iso-Seq™ Method: Sample Prep and Experimental Design for Full-Length cDNA Sequencing
•Thursday Feb 12: Iso-Seq™ Analysis & Beyond: Advanced Bioinformatics for Transcriptome Sequencing Using Long Reads
Iso-Seq ™ Method: Sample Prep and Experimental Design for Full-Length cDNA Sequencing
In this webinar we will present the recent Iso-Seq template preparation protocol updates for creating full-length cDNAs and discuss considerations for experimental design.
Topics Covered
•Why full-length transcript sequences matter
•Overview of Iso-Seq template preparation methods
•Updates to protocol allowing for sequencing of transcripts up to ˜10 kb
•Methods for size fractionation
•Applications of the Iso-Seq method
•Targeted transcript sequencing
•Normalization
Who should attend:
Biologists and technicians who are running Iso-Seq experiments and anyone who is interested in learning more about using long read sequencing to study full-length transcripts.
Recommended Pre-reading:
•General information on Isoform Sequencing
•
•User Bulletin - Guidelines for Preparing cDNA Libraries for Isoform Sequencing (Iso-Seq™)
Click on your preferred time below to register:
•Wednesday, February 11 8:00 a.m. PST
Wednesday, February 11 5:00 p.m. PST
Presenter Biography
Tyson A. Clark, Ph.D.
Senior Manager, Next Generation Applications and Technologies
In 2002, Tyson received his doctorate degree in Molecular Biology from the University of California, Santa Cruz. He was a pioneer in the use of microarrays to study alternative splicing events on a genome-wide scale. After working in the gene expression space at Affymetrix, Tyson joined Pacific Biosciences in 2009. His energy is focused on the development of new applications for use on the PacBio RS II.
Iso-Seq™ Analysis & Beyond: Advanced Bioinformatics for Transcriptome Sequencing Using Long Reads
In this webinar we will demonstrate how to run the Iso-Seq bioinformatics software pipeline that is part of PacBio's SMRTAnalysis software suite. Both the web portal interface (SMRT Portal) and the command line version will be introduced. In addition, we will be using the community version of Iso-Seq (pbtranscript-tofu) and other community tools to perform additional analyses.
Topics Covered
•Iso-Seq Bioinformatics Pipeline*: ?running from SMRTPortal web interface
?running from command line
?interpreting Iso-Seq output results
?troubleshooting
•Beyond Iso-Seq**: ?visualizing isoforms
?comparing against reference transcript annotations
?look for fusion gene candidates
?open reading frame prediction
?and more...
* Demonstrated using the latest official Iso-Seq protocol from SMRTAnalysis 2.3
** Enabled through use of community tools
Who should attend:
Bioinformaticians interested in running and analyzing PacBio Iso-Seq datasets. Familiarity with Unix and Python is expected.
Recommended Pre-reading::
•Basic understanding of the PacBio sequencing format
•Official Iso-Seq resource page
Click on your preferred time below to register:
•Thursday, February 12 8:00 a.m. PST
Thursday, February 12 5:00 p.m. PST
Presenter Biography
Elizabeth Tseng
Staff Scientist, Pacific Biosciences
Elizabeth obtained her doctorate degree in Computer Science & Engineering from the University of Washington in 2012. Her thesis work focused on the computational discovery of bacterial non-coding RNAs and gut microbiome. After joining PacBio, she decided to give prokaryotes a break and now supports and develops eukaryotic transcriptome-related collaborations.
Recent PACB News
- Ambry Genetics and PacBio Announce Collaboration to Sequence Up to 7,000 Human Genomes Aimed at Providing Answers for Families Battling Rare Diseases • PR Newswire (US) • 05/15/2024 01:45:00 PM
- Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers • Edgar (US Regulatory) • 05/09/2024 08:33:12 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:21:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 08:12:15 PM
- PacBio Announces First Quarter 2024 Financial Results • PR Newswire (US) • 05/09/2024 08:05:00 PM
- PacBio Announces Preliminary First Quarter 2024 Revenue and Updates 2024 Revenue Guidance • PR Newswire (US) • 04/16/2024 12:05:00 PM
- Estonia National Biobank Selects PacBio to Sequence 10,000 Whole Genomes • PR Newswire (US) • 03/27/2024 12:00:00 PM
- PacBio Grants Equity Incentive Award to New Employee • PR Newswire (US) • 03/22/2024 08:30:00 PM
- PacBio Announces PureTarget™ Repeat Expansion Panel, Expanding its Portfolio of End-to-End Clinical Research Solutions • PR Newswire (US) • 03/12/2024 01:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 10:36:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 10:30:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 10:26:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 10:22:45 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2024 11:32:39 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2024 11:22:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 09:55:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 09:36:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 09:25:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 09:19:42 PM
- PacBio to Present at Upcoming Investor Conferences • PR Newswire (US) • 02/26/2024 09:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 11:25:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 11:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 11:17:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 11:07:18 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/20/2024 09:17:12 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM